Calmark streamlines the organization to increase the focus on sales of the company's fully developed products

Nov

Calmark Sweden AB (publ) announced today that the company has initiated measures to streamline the internal organization and to prioritize the sales of the company's fully developed products. The development projects for new biomarkers are paused until further notice and the organization is thus reduced by 25%. The ambition is for Calmark to become cash flow positive in the coming year.

This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 28 2022, 09:45 CET.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

‍

Calmark streamlines the organization to increase the focus on sales of the company's fully developed products

Calmark streamlines the organization to increase the focus on sales of the company's fully developed products

Pressmeddelanden

Press releases